Get the Stockscreener App
37.64
4.04%
1.46
After Hours:
37.64
Cytokinetics Inc stock is traded at $37.64, with a volume of 1.78M.
It is up +4.04% in the last 24 hours and up +13.92% over the past month.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
See More
Previous Close:
$36.18
Open:
$35.68
24h Volume:
1.78M
Relative Volume:
1.06
Market Cap:
$4.50B
Revenue:
$18.47M
Net Income/Loss:
$-589.53M
P/E Ratio:
-7.1559
EPS:
-5.26
Net Cash Flow:
$-399.80M
1W Performance:
+0.88%
1M Performance:
+13.92%
6M Performance:
-23.90%
1Y Performance:
-36.21%
1-Day Range:
$35.50
$38.59
1-Week Range:
$35.50
$38.59
52-Week Range:
$29.31
$59.80
Cytokinetics Inc Stock (CYTK) Company Profile
Name
Cytokinetics Inc
Sector
Industry
Phone
(650) 624-3000
Address
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
37.64 | 4.32B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Resumed | Raymond James | Mkt Perform |
| Apr-24-25 | Initiated | Barclays | Overweight |
| Feb-07-25 | Initiated | Citigroup | Buy |
| Jan-22-25 | Initiated | Stifel | Buy |
| Nov-08-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-13-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Jan-05-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-07-23 | Initiated | B. Riley Securities | Buy |
| Aug-15-23 | Initiated | SVB Securities | Outperform |
| Feb-17-23 | Initiated | BofA Securities | Neutral |
| Dec-23-22 | Reiterated | Needham | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jan-28-22 | Initiated | Goldman | Buy |
| Dec-22-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | JP Morgan | Overweight |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Feb-18-21 | Initiated | Barclays | Overweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-20 | Initiated | Goldman | Neutral |
| Jul-10-20 | Initiated | Raymond James | Strong Buy |
| May-05-20 | Initiated | Mizuho | Buy |
| Apr-09-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-10-18 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-22-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-22-17 | Downgrade | Needham | Strong Buy → Buy |
| Nov-21-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Initiated | Morgan Stanley | Overweight |
| Mar-08-17 | Initiated | Rodman & Renshaw | Buy |
| Feb-06-17 | Upgrade | Needham | Buy → Strong Buy |
| Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-28-16 | Reiterated | Needham | Buy |
| Nov-10-15 | Reiterated | FBR Capital | Outperform |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Jul-24-15 | Reiterated | MLV & Co | Buy |
| Dec-31-14 | Reiterated | ROTH Capital | Buy |
| Nov-04-14 | Upgrade | MLV & Co | Hold → Buy |
| Apr-28-14 | Reiterated | Needham | Buy |
View All
Cytokinetics Inc Stock (CYTK) Latest News
Shareholder Rights Advocates at Levi & Korsinsky Investigate Cytokinetics, Incorporated (CYTK) Regarding Possible Securities Fraud Violations - ACCESS Newswire
Levi & Korsinsky Announces an Investigation on Behalf of Cytokinetics, Incorporated (CYTK) Shareholders Who May Have Been Affected by Fraud - ACCESS Newswire
Institutional Tools Highlight Unusual Flow in Cytokinetics IncorporatedWeekly Chart Analysis With Entry Advice Provided - metal.it
Raymond James downgrades Cytokinetics stock rating to Market Perform By Investing.com - Investing.com Canada
Cytokinetics, Incorporated Investigated by Shareholder Rights AdvocatesInvestors Should Contact Levi & Korsinsky Regarding Potential Securities Law ViolationsCYTK - ACCESS Newswire
Cytokinetics Incorporated Stock Support and Resistance Levels You Should KnowRisk Controlled Picks With Real Returns Outlined - metal.it
Why Cytokinetics Incorporated stock attracts strong analyst attentionEarnings Play Trade Plan With Alerts Shared - metal.it
Cytokinetics Incorporated Earnings Report Breakdown: What Investors Should KnowInvestment Playbook for Growing Markets Shared - metal.it
Piper Sandler Maintains a Buy Rating on Cytokinetics (CYTK) With a $107 PT - MSN
Cytokinetics, Incorporated (CYTK) Shareholders May Have Been Affected by FraudLevi & Korsinsky Investigates - ACCESS Newswire
What makes Cytokinetics Incorporated stock price move sharplyBuild wealth faster with consistent investment plans - jammulinksnews.com
How strong is Cytokinetics Incorporated company’s balance sheetUnlock exclusive stock market forecasts - jammulinksnews.com
What are analysts’ price targets for Cytokinetics Incorporated in the next 12 monthsDiscover undervalued opportunities early - jammulinksnews.com
Cytokinetics (CYTK): Is the FDA Delay a Buying Opportunity for Aficamten's Long-Term Payoff? - AInvest
Levi & Korsinsky Reminds Cytokinetics, Incorporated Investors of the Ongoing Investigation into Potential Violations of Securities LawsCYTK - ACCESS Newswire
Cytokinetics Incorporated Stock Analysis and ForecastSpectacular growth rates - PrintWeekIndia
Cytokinetics Sets Key Q2 Earnings Date: What Investors Should Watch on August 7 - Stock Titan
What risks could impact Cytokinetics Incorporated stock performanceExceptional trading performance - jammulinksnews.com
Top Executive Sells Cytokinetics Stock in a Major Move - TipRanks
What drives Cytokinetics Incorporated stock priceRapid portfolio appreciation - Autocar Professional
What analysts say about Cytokinetics Incorporated stockFree Stock Market Knowledge Sharing - jammulinksnews.com
Is Cytokinetics Incorporated a good long term investmentOutstanding trading profits - jammulinksnews.com
Shareholders that lost money on Cytokinetics, Incorporated (CYTK) should contact Levi & Korsinsky about Securities Fraud InvestigationCYTK - ACCESS Newswire
Cytokinetics, Incorporated INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Cytokinetics, Incorporated (CYTK) - ACCESS Newswire
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Cytokinetics Awards 220,000 Shares in Employee Stock Grants at $38.68 Strike Price - Stock Titan
Cytokinetics’ Aficamten Study: A New Hope for Pediatric Heart Patients - TipRanks
Cytokinetics CEO Makes a Significant Stock Move! - TipRanks
Cytokinetics (CYTK) CEO Blum sells $190k in stock By Investing.com - Investing.com Nigeria
Cytokinetics (CYTK) CEO Blum sells $190k in stock - Investing.com
CYTK ALERTLevi & Korsinsky Has Commenced an Investigation on Behalf of Cytokinetics, Incorporated Shareholders Who Lost Money - ACCESS Newswire
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025 - The Manila Times
Cytokinetics to Showcase Positive Aficamten Results for Obstructive Hypertrophic Cardiomyopathy at European Society of Cardiology Congress 2025 - Nasdaq
Cytokinetics(CYTK) Soars 6.93% on Analyst Optimism - AInvest
Cytokinetics, Incorporated Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud AllegationsCYTK - ACCESS Newswire
Cytokinetics Inc Stock (CYTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):